NanoViricides submits DengueCide for orphan drug status

NanoViricides, Inc., announced on Monday that it has filed for orphan drug status with the Office of Orphan Product Development, a part of the U.S. Food and Drug Administration, for its drug candidate DengueCide.

DenugeCide is a nanoviricide that has shown to have a high effectiveness in animal models that are infected with the dengue virus. It is also shown to work in cell cultures of the dengue virus.

Dengue fever, also known as breakbone fever, is a virus spread by mosquitoes that is usually found in tropical regions. Symptoms of dengue fever include fever, headache, muscle and joint pains and a signature skin rash. Some cases of dengue fever escalate to become a potentially life threatening illness called dengue hemorrhagic fever, which results in bleeding and blood plasma leakage.

The orphan drug is a term used for drugs that are pharmaceutical agents made to specifically treat a rare medical condition. The FDA's orphan drug status encourages pharmaceutical companies to develop drugs for otherwise unprofitable disease, which could result in clinical trial tax incentives and priority review vouchers estimated to be worth between $200 and $600 million.

There are currently no effective drug or vaccine treatments for dengue virus. DengueCide's filing for orphan status is a step towards making a drug able to combat the disease.